Naftopidil

Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2].

Product Specifications

CAS Number

[57149-07-2]

Product Name Alternative

KT-611; BM-15275

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/naftopidil.html

Purity

98.47

Solubility

DMSO : 33.33 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

OC(CN1CCN(C(C=CC=C2)=C2OC)CC1)COC3=CC=CC4=CC=CC=C34

Molecular Formula

C24H28N2O3

Molecular Weight

392.49

Precautions

H302, H315, H319, H335

References & Citations

[2]R Takei, et al. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol. 1999 Apr;79 (4) :447-54.|[1]Yasuhide Hori, et al. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res (Phila) . 2011 Jan;4 (1) :87-96.